Nuformix Plc
LLSE:NFX0.10
GBX
-0.01
(-9.09%)
ISIN
GB00BYW79Y38
Return %
Stock
S&P 500
1Y
-66.61
14.20
3Y
-61.57
81.12
5Y
-92.73
68.34
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.Company Description
- CEO
- Daniel John Gooding
- Full Time Employees
- 3
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 60 Gracechurch Street London GL United Kingdom EC3V 0HR
- IPO Date
- Dec 17, 2015
- Website
- nuformix.com
- Similar Companies
- Business
- Nuformix plc Nuformix plc is a United Kingdom-based pharmaceutical development company that targets unmet medical needs in fibrosis and oncology through drug repurposing and the creation of novel crystalline drug forms with improved physical properties for enhanced dosage, delivery or presentation. Incorporated in 2015 and headquartered at 6th Floor, 60 Gracechurch Street, London EC3V 0HR, the company operates primarily through its subsidiary Nuformix Technologies Limited and focuses on preclinical assets including NXP002, a proprietary inhaled form of tranilast for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis; NXP001, a new form of aprepitant for oncology supportive care that was exclusively licensed to Oxilio Ltd with Nuformix retaining development milestones and royalties capped at £2 million annually; and NXP004, novel cocrystal forms of olaparib offering potential improvements in dissolution, bioavailability and manufacturing cost over AstraZeneca's Lynparza for oncology indications. The company leverages a network of external contractors for outsourced R&D across preclinical to clinical stages and pursues early licensing opportunities in global markets, particularly the US where IPF affects approximately 100,000 patients annually and represents a projected $6.45 billion market by 2031. Recent developments include multiple NXP002 patent grants in the US, Japan and Europe for substance of matter and method of use; a positive opinion from the European Medicines Agency for Orphan Drug Designation in IPF; plans for US FDA Orphan Drug Designation submission; a May 2025 fundraising of £210,000 to advance NXP002 partnering and orphan drug applications; an October 2025 underwritten open offer raising £228,081 for inhaled therapeutic window assessment, IP maintenance and out-licensing discussions; a November 2024 placing and subscription raising £300,000 at 0.05 pence per share; relocation of its registered office; and appointment of a new company secretary.